| Unique ID issued by UMIN | UMIN000059714 |
|---|---|
| Receipt number | R000068297 |
| Scientific Title | The importance of microvascular dysfunction in patients with chronic thromboembolic pulmonary hypertension |
| Date of disclosure of the study information | 2025/11/17 |
| Last modified on | 2025/11/10 10:06:10 |
The importance of microvascular dysfunction in patients with chronic thromboembolic pulmonary hypertension
Microcascular dysfunction in patients with CTEPH
The importance of microvascular dysfunction in patients with chronic thromboembolic pulmonary hypertension
Microcascular dysfunction in patients with CTEPH
| Japan |
Chronic thromboembolic pulmonary hypertension
| Cardiology |
Others
NO
In this study, we will observe the degree of pulmonary microvascular dysfunction in CTEPH patients undergoing BPA treatment using a pressure wire and the CoroFlow Cardiovascular System. Since the effectiveness of BPA treatment strategies using this system has been reported in previous studies, the aim of this study is to deepen the understanding of the pathophysiology of pulmonary microvascular dysfunction from the data obtained during BPA treatment using this system. As mentioned above, there is currently no established index for quantifying the degree of pulmonary microcirculation. Using microcirculation indices obtained with a pressure wire and the CoroFlow Cardiovascular System, we aim to establish indicators that contribute to predicting post-BPA exercise tolerance and optimizing the distribution of pulmonary blood flow.
Others
None
Exploratory
Explanatory
Not applicable
The following measurements will be performed three months after the final BPA: - Right heart catheterization (PAWP, PAP, RVP, RAP, CO, CI)- Exercise stress right heart catheterization (mPAP/CO slope, PAWP/CO slope)
1. Patient Basic Information: WHO-FC, emPHasis-10
2. Blood Test Results: Improvement in BNP and Nt-ProBNP
3. Imaging Results: Improvement in pulmonary blood flow on chest contrast CT and lung perfusion scintigraphy
4. Physiological Tests: Pulmonary function tests , transthoracic echocardiography, cardiopulmonary exercise test, 6-minute walk test
5. Blood Gas Tests (arterial, venous)
6. BPA Treatment Details (number of sessions, maximum balloon size, amount of contrast agent used, radiation exposure, fluoroscopy time)
Observational
| 20 | years-old | <= |
| Not applicable |
Male and Female
1. Patients diagnosed with CTEPH
2. Patients judged eligible for BPA treatment
3. Patients aged 20 years or older at the time of obtaining consent
None
50
| 1st name | Tomohiro |
| Middle name | |
| Last name | Yamaguchi |
Osaka Metropolitan University Graduate School of Medicine
Cardiovascular Medicine
545-8585
1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan
06-6645-3801
tomohiro.y.1987@gmail.com
| 1st name | Tomohiro |
| Middle name | |
| Last name | Yamaguchi |
Osaka Metropolitan University Graduate School of Medicine
Cardiovascular Medicine
545-8585
1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan
06-6645-3801
tomohiro.y.1987@gmail.com
Osaka Metropolitan University
Tomohiro Yamaguchi
None
Other
Ethical Committee of Osaka Metropolitan University Graduate School of Medicine
6th Floor, Abeno Medics, 1-2-7 Asahimachi, Abeno Ward, Osaka City
06-6645-3456
gr-a-knky-ethics@omu.ac.jp
NO
| 2025 | Year | 11 | Month | 17 | Day |
Unpublished
Preinitiation
| 2025 | Year | 10 | Month | 27 | Day |
| 2025 | Year | 10 | Month | 27 | Day |
| 2025 | Year | 11 | Month | 17 | Day |
| 2030 | Year | 03 | Month | 31 | Day |
None
| 2025 | Year | 11 | Month | 10 | Day |
| 2025 | Year | 11 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000068297